Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines), By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies), By Region & Competition, 2021-2031F

January 2026 | 180 pages | ID: C7D7DA948FD2EN
TechSci Research

Abstracts

The Global Cancer Biological Therapy Market is projected to expand from USD 116.12 Billion in 2025 to USD 182.03 Billion by 2031, achieving a compound annual growth rate of 7.78%. Cancer biological therapy refers to a specialized class of treatments that utilize living organisms, their derivatives, or laboratory-engineered versions to prompt the immune system to identify and destroy malignant cells. The primary forces driving this market include the rising global incidence of cancer and a clinical shift toward precision medicine, which prioritizes targeted biological interventions over traditional non-specific treatments. As reported by the American Cancer Society, the United States was expected to see 2,001,140 new cancer cases in 2024, highlighting the substantial and expanding patient population in need of effective therapeutic options.

Despite robust demand, the market faces significant hurdles due to the prohibitive costs associated with developing and manufacturing these complex biologics. This financial barrier leads to high treatment prices that strain healthcare budgets and restrict patient access, particularly in developing regions with limited reimbursement frameworks.

Market Driver

Accelerated regulatory pathways for new biologics have fundamentally transformed the Global Cancer Biological Therapy Market by shortening the timeline between clinical validation and patient availability. Regulatory agencies have increasingly adopted expedited review processes to speed up the entry of innovative therapies, particularly for rare and refractory cancers. This streamlined environment not only encourages pharmaceutical innovation but also ensures the rapid broadening of treatment options. For instance, the American Association for Cancer Research noted in its January 2024 'Cancer Research Catalyst' that the U.S. Food and Drug Administration approved 45 oncology drugs in 2023, demonstrating the continued momentum of market authorizations for these complex interventions.

Concurrently, the growing adoption of targeted monoclonal antibodies remains a primary driver of market revenue and clinical practice. These biologic agents have become the standard of care for numerous solid tumors, driving significant commercial growth through high utilization in both first-line and adjuvant settings. The financial scale of this segment is illustrated by the performance of leading checkpoint inhibitors; according to Merck & Co.?s 'Fourth-Quarter and Full-Year 2023 Financial Results' released in February 2024, annual sales of Keytruda rose 19% to $25.0 billion in 2023. This commercial success is supported by massive capital investment in innovation, as evidenced by Bristol Myers Squibb?s '2023 Annual Report' from March 2024, which reported a $9.3 billion investment in research and development to advance its portfolio.

Market Challenge

The high costs associated with the development and manufacturing of complex biologics represent a major obstacle to the growth of the Global Cancer Biological Therapy Market. These elevated production expenses force pharmaceutical companies to adopt premium pricing strategies to recoup their research and development investments, thereby straining healthcare budgets and insurance systems worldwide. Consequently, payers in both developed and developing regions are enforcing stricter reimbursement criteria, often delaying or denying coverage for these advanced treatments. This financial friction limits the accessible patient population and impedes the market penetration of otherwise clinically effective therapies.

According to the American Cancer Society, in 2025, the annual list price for many new cancer prescription medicines exceeded $100,000, creating a severe financial burden for patients and healthcare systems. This pricing structure directly hampers market growth by fueling high rates of financial toxicity, which frequently compels patients to forgo or discontinue necessary treatment. The resulting gap between clinical necessity and economic feasibility reduces the commercial adoption of biological therapies, preventing the market from realizing its full revenue potential.

Market Trends

The rapid adoption of oncology biosimilars is fundamentally restructuring the market by introducing cost-effective alternatives to expensive reference biologics. This trend is primarily driven by the patent expiration of major blockbuster drugs and the intensified need for healthcare systems to optimize spending without compromising clinical outcomes. By offering clinically equivalent therapeutic options at reduced prices, biosimilars are expanding patient access to essential biological treatments, particularly in resource-constrained settings. This economic shift is significant; according to the Association for Accessible Medicines' '2025 U.S. Generic & Biosimilar Medicines Savings Report' from September 2025, the biosimilars industry has generated $56.2 billion in cumulative savings for patients and the healthcare system since these agents first entered the market.

At the same time, a surge in the development of antibody-drug conjugates (ADCs) is establishing a new paradigm in targeted cancer intervention. Pharmaceutical companies are heavily investing in this modality, which combines the specificity of monoclonal antibodies with the potency of cytotoxic agents to deliver payloads directly to tumor cells while minimizing off-target toxicity. This focus has translated into rapid commercial growth for approved ADCs, validating their potential to replace conventional chemotherapy in multiple indications. According to Pfizer Inc.?s 'Second-Quarter 2025 Earnings' report from August 2025, global sales of the antibody-drug conjugate Padcev increased 38% year-over-year to reach $542 million, underscoring the high clinical demand and market uptake for these precision therapeutics.

Key Market Players

• F Hoffmann-La Roche Ltd
• Novartis AG
• Merck KgAa
• Amgen Inc
• GSK PLC
• Celgene Corp
• Pfizer Inc
• Zydus Lifesciences Ltd
• Sun Pharmaceutical Industries Ltd
• Bayer AG

Report Scope

In this report, the Global Cancer Biological Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cancer Biological Therapy Market, By Product
• Cancer Growth Blockers
• Monoclonal Antibodies
• Vaccines
• Cancer Biological Therapy Market, By Distribution Channel
• Hospitals
• Retail & Mail Order Pharmacies
• Cancer Biological Therapy Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biological Therapy Market.

Available Customizations:

Global Cancer Biological Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
  5.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies)
  5.2.3. By Region
  5.2.4. By Company (2025)
5.3. Market Map

6. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Product
  6.2.2. By Distribution Channel
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Cancer Biological Therapy Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Product
      6.3.1.2.2. By Distribution Channel
  6.3.2. Canada Cancer Biological Therapy Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Product
      6.3.2.2.2. By Distribution Channel
  6.3.3. Mexico Cancer Biological Therapy Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Product
      6.3.3.2.2. By Distribution Channel

7. EUROPE CANCER BIOLOGICAL THERAPY MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Product
  7.2.2. By Distribution Channel
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Cancer Biological Therapy Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Product
      7.3.1.2.2. By Distribution Channel
  7.3.2. France Cancer Biological Therapy Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Product
      7.3.2.2.2. By Distribution Channel
  7.3.3. United Kingdom Cancer Biological Therapy Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Product
      7.3.3.2.2. By Distribution Channel
  7.3.4. Italy Cancer Biological Therapy Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Product
      7.3.4.2.2. By Distribution Channel
  7.3.5. Spain Cancer Biological Therapy Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Product
      7.3.5.2.2. By Distribution Channel

8. ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Product
  8.2.2. By Distribution Channel
  8.2.3. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Cancer Biological Therapy Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Product
      8.3.1.2.2. By Distribution Channel
  8.3.2. India Cancer Biological Therapy Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Product
      8.3.2.2.2. By Distribution Channel
  8.3.3. Japan Cancer Biological Therapy Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Product
      8.3.3.2.2. By Distribution Channel
  8.3.4. South Korea Cancer Biological Therapy Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Product
      8.3.4.2.2. By Distribution Channel
  8.3.5. Australia Cancer Biological Therapy Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Product
      8.3.5.2.2. By Distribution Channel

9. MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Product
  9.2.2. By Distribution Channel
  9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Cancer Biological Therapy Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Product
      9.3.1.2.2. By Distribution Channel
  9.3.2. UAE Cancer Biological Therapy Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Product
      9.3.2.2.2. By Distribution Channel
  9.3.3. South Africa Cancer Biological Therapy Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Product
      9.3.3.2.2. By Distribution Channel

10. SOUTH AMERICA CANCER BIOLOGICAL THERAPY MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Product
  10.2.2. By Distribution Channel
  10.2.3. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Cancer Biological Therapy Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Product
      10.3.1.2.2. By Distribution Channel
  10.3.2. Colombia Cancer Biological Therapy Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Product
      10.3.2.2.2. By Distribution Channel
  10.3.3. Argentina Cancer Biological Therapy Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Product
      10.3.3.2.2. By Distribution Channel

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. F Hoffmann-La Roche Ltd
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Merck KgAa
15.4. Amgen Inc
15.5. GSK PLC
15.6. Celgene Corp
15.7. Pfizer Inc
15.8. Zydus Lifesciences Ltd
15.9. Sun Pharmaceutical Industries Ltd
15.10. Bayer AG

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER